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MetallopeptidaseMatrix metalloproteinases (MMPs) are zinc-dependent protein and peptide hydrolases. They have been
almost exclusively studied in vertebrates and 23 paralogs are present in humans. They are widely involved in
metabolism regulation through both extensive protein degradation and selective peptide-bond hydrolysis. If
MMPs are not subjected to exquisite spatial and temporal control, they become destructive, which can lead to
pathologies such as arthritis, inﬂammation, and cancer. The main therapeutic strategy to combat the
dysregulation of MMPs is the design of drugs to target their catalytic domains, for which purpose detailed
structural knowledge is essential. The catalytic domains of 13 MMPs have been structurally analyzed so far
and they belong to the “metzincin” clan of metalloendopeptidases. These compact, spherical, ∼165-residue
molecules are divided by a shallow substrate-binding crevice into an upper and a lower sub-domain. The
molecules have an extended zinc-binding motif, HEXXHXXGXXH, which contains three zinc-binding
histidines and a glutamate that acts as a general base/acid during catalysis. In addition, a conserved
methionine lying within a “Met-turn” provides a hydrophobic base for the zinc-binding site. Further
earmarks of MMPs are three α-helices and a ﬁve-stranded β-sheet, as well as at least two calcium sites and a
second zinc site with structural functions. Most MMPs are secreted as inactive zymogens with an N-terminal
∼80-residue pro-domain, which folds into a three-helix globular domain and inhibits the catalytic zinc
through a cysteine imbedded in a conserved motif, PRCGXPD. Removal of the pro-domain enables access of a
catalytic solvent molecule and substrate molecules to the active-site cleft, which harbors a hydrophobic S1′-
pocket as main determinant of speciﬁcity. Together with the catalytic zinc ion, this pocket has been targeted
since the onset of drug development against MMPs. However, the inability of ﬁrst- and second-generation
inhibitors to distinguish between different MMPs led to failures in clinical trials. More recent approaches
have produced highly speciﬁc inhibitors to tackle selected MMPs, thus anticipating the development of more
successful drugs in the near future. Further strategies should include the detailed structural characterization
of the remaining ten MMPs to assist in achieving higher drug selectivity. In this review, we discuss the
general architecture of MMP catalytic domains and its implication in function, zymogenic activation, and
drug design.
© 2009 Elsevier B.V. All rights reserved.1. Physiological backgroundMMPs, also called matrixins, vertebrate collagenases, and matrix
metalloproteinases, are secreted ormembrane-bound zinc-dependent
protein and peptide hydrolases, which constitute a separate family
within the “metzincin” clan of metallopeptidases (MPs) [1–6]. Theyotease; ADAMTS, ADAM with
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ll rights reserved.were discovered 47 years ago as the agents responsible for tail
resorption during frog metamorphosis [7–9] and have since been
identiﬁed as the main processors of extracellular matrix (ECM)
components [2]. As such, they participate in physiological processes
involving tissue turnover and repair during blastocyst implantation,
ovulation, postpartum and post-lactational involution, bone resorp-
tion, wound healing, etc. Such processing capacity is also required
during embryogenesis and angiogenesis. More recently, MMPs have
also been implicated in more sophisticated processes than mere ECM
turnover [10,11]. These include the activation or inactivation of other
proteins through limited proteolysis of selected bonds, as well as the
shedding of membrane-anchored forms into circulation. Substrates
include other (pro-)proteases, protease inhibitors, clotting factors,
antimicrobial peptides, chemotactic and adhesion molecules, and
growth factors, hormones, cytokines, as well as their receptors and
binding proteins. In such shedding functions, MMPs overlap in
substrate speciﬁcity, spatial and temporal location, and in their
proclivity to cleave upstream of hydrophobic residues, typically
Table 2
Access codes corresponding to experimental three-dimensional structures containing
at least the catalytic domain of MMPs as deposited with the Protein Data Bank (www.
ebi.ac.uk/msd/index.html or www.pdb.org; closing date: January 26, 2009).
Fibroblast collagenase (MMP-1)
(Homo sapiens ; Sus scrofa)
966c 1ayk 1cge 1cgf 1cgl 1fbl 1hfc 1mnc 2ayk
2tcl 3ayk 4ayk 1su3 2j0t 2clt
Gelatinase A (MMP-2) (H. sapiens) 1ck7 1hov 1qib 1gxd 1eak
Stromelysin-1 (MMP-3) (H. sapiens) 1b3d 1b8y 1biw 1bm6 1bqo 1c3i 1caq 1ciz
1cqr 3usn 1uea 2d1o 1c8t 2jt6 2jt5 2jnp
1d5j 1d7x 1d8f 1d8m1g051g491g4k 1hfs 1hy7
1sln 1slm 1qia 1qic 1ums 1umt 1usn 2srt 2usn
Matrilysin (MMP-7) (H. sapiens) 1 mmp 1 mmq 1 mmr 2ddy
Neutrophil collagenase (MMP-8)
(H. sapiens)
1jan 1a85 1a86 1bzs 1i73 1i76 1jao 1jap 1jaq
1jh11jj9 1 kbc 1 mmb 1mnc 1zvx 2oy4 1zs0
1zp5 2oy2 1jh1 3dpe 3dpf 3dng
Gelatinase B (MMP-9) (H. sapiens) 1gkc 1gkd 1l6j 2ow0 2ow1 2ow2 2ovz 2ovx
Stromelysin-2 (MMP-10) (H. sapiens) 1q3a
Stromelysin-3 (MMP-11) (Mus musculus) 1hv5
Macrophage elastase (MMP-12)
(H. sapiens)
1jiz 1jk3 2z2d 2k2g 3ba0 2oxu 2oxz 2oxw
2hu6
1z3j 1ycm 1y93 1rmz 1os9 1os2 2poj 1utz 1utt
1ros 2w0d 3ehx 3ehy 1zrg 2jpv 3f15 3f16 3f17
3f18 3f19 3f1a 2k9c 2jxy
Collagenase-3 (MMP-13)
(H. sapiens; M. musculus)
456c 830c 1cxv 1eub 1ﬂs 1fm1 2pjt 2ozr 2ow9
2e2d 2d1n 1ztq 1you 1xur 1xud 1xuc 3elm
MT1-MMP (MMP-14) (H. sapiens) 1bqq 1buv
MT3-MMP (MMP-16) (H. sapiens) 1rm8
Enamelysin (MMP-20) (H. sapiens) 2jsd
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adamalysins (ADAM is an acronym for a disintegrin and metallo-
protease; [12–14]). If this formidable proteolytic potential of
MMPs is not subjected to ﬁne-tuned control, dysregulation can
give rise to degradation and ensuing pathologies. This happens
during inﬂammation, ulceration, arthritis, periodontitis, cardiovas-
cular disease, ﬁbrosis, and emphysema. Further consequences of
deregulated MMP activity include cancer-associated processes like
tumorigenesis and tumor neovascularisation, invasion and metas-
tasis, as well as apoptosis, intestinal defense activation, and
pathologies of the nervous system, such as stroke and Alzheimer's
disease [15].
2. Classiﬁcation and modular organization
Open reading frames with high sequence similarity to MMP
catalytic domains are present across almost all kingdoms of life, from
archaebacteria to sea urchins, and from viruses to worms and plants
[3]. In humans, there are 23 paralogs (numbered 1 to 3, 7 to 17, 19 to
21, and 23 to 28 for historical reasons; there are two identical forms
for MMP-23, encoded by two genes, mmp-23a and mmpP-23b, see
http://degradome.uniovi.es/met.html#M10; [16,17]). MMPs can be
divided into: (i) true collagenases, which cut triple-helical collagen
at a single site across the three chains, giving rise to products 3/4 and
1/4 of the length of the original molecule; (ii) gelatinases, which
target denatured collagens and gelatins; and (iii) stromelysins,
which have broad speciﬁcity and may degrade proteoglycans.
Another classiﬁcation identiﬁes matrilysins, archetypal MMPs,
convertase-activatable MMPs, and gelatinases [11,15,18–23]. MMPs
are mosaic proteins, each constituted by a modular combination of
inserts and domains. These may include, from N- to C-terminus, a
signal peptide for secretion; a ∼80-residue zymogenic pro-peptide; a
∼165-residue zinc- and calcium-dependent catalytic MP domain
(Table 1); a 15-to-65-residue linker region; and a ∼200-residue
hemopexin-like domain for collagen binding, pro-MMP activation,
and dimerization [24,25]. Further possible insertions include
ﬁbronectin type-II-related domains for interaction with collagensTable 1
Statistics on the pro- and catalytic domains of structurally characterized MMPs.
MMP Access
code⁎
Catalytic
domain
Catalytic
domain
length
NTS
residues+
CTS
residues++
Pro-domain
length⁎⁎
1 P03956 F100–G261 162 126 36 80
2 P08253 Y110–G446# 160 124 36 80
3 P08254 F100–G264 165 126 39 82
7 P09237 Y95–G259 165 127 38 77
8 P22894 F99–G262 164 126 38 79
9 P14780 F107–G444# 160 124 36 74
10 P09238 F99–G263 165 126 39 81
11 P24347 F98–G258 161 130 31 66
12 P39900 F100–G263 164 126 38 83
13 P45452 Y104–G267 164 126 38 84
14 P50281 Y112–G284 173 135 38 91
16 P51512 Y120–G291 172 134 38 88
20 O60882 Y108–G271 164 126 38 85
⁎ Sequence entry according to UniProt (www.uniprot.org). The extent of the pro-
domain as annotated in the entry does not always correspond to the experimentally
determined sequence stretch. Only the human orthologs were considered.
⁎⁎ Based on the estimated length of the signal peptide and the N-terminus of the
mature protease.
+ Residues between the N-terminus and the glycine of the zinc-binding consensus
sequence.
++ Residues between the glycine of the zinc-binding consensus sequence and the
C-terminal glycine at the end of helix αC.
# Gelatinases A (MMP-2) and B (MMP-9) have three ﬁbronectin type-II repeats
totaling 177 and 178 residues, respectively, inserted into their catalytic domains within
LβVαB.and gelatins, uniquely found in gelatinases A (MMP-2) and B (MMP-
9); a collagen type-V-like insert; a vitronectin-like insertion domain; a
cysteine-rich, proline-rich and interleukin-1 receptor-like domain; an
immunoglobulin-like domain; a glycosyl phosphatidylinositol linkage
signal; a type-I or type-II trans-membrane domain; a stem or “linker 2”
region downstream of the hemopexin-like domain; and a cytoplasmic
tail [3,20,25,26]. Those MMPs bearing a membrane anchor give rise to
the MT-MMP subfamily (MT1-MMP to MT6-MMP; in plain MMP
nomenclature they are, respectively, MMP-14 to-17, MMP-24, and
MMP-25).
3. Activity regulation
MMPs are regulated via modulation of gene expression, compart-
mentalization, and inhibition by protein inhibitors. Most MMPs are
not constitutively transcribed, but are expressed after external
induction by cytokines and growth factors. In addition, some MMPs
are stored in inﬂammatory cell granules, which restrict their compass
of action. Another regulatory mechanism is provided by zymogeni-
city. All MMPs except MMP-23 comprise a pro-domain upstream of
the catalytic domain, and activation proceeds through its removal
(see Section 7.). This is catalyzed by furin-like pro-hormone
convertases, by members of the plasminogen/plasmin cascade or
by other MMPs [27–31]. Once MMPs have been released to the
extracellular space or anchored to the membrane and activated, they
are kept in check byα2-macroglobulin (non-speciﬁcally) and by their
endogenous tissue inhibitors, the co-secreted or ECM-anchored 22-
to-29-kDa tissue inhibitors of metalloproteinases (TIMPs; [2,32]).
Four different forms (TIMP-1 to TIMP-4) have been described to date.
They inhibit active MMPs with relatively low selectivity, forming
tight 1:1 complexes and also participate in pro-MMP activation;
suppression of tumour-growth, invasion and metastasis; morphol-
ogy modulation; cell-growth promotion; matrix binding; inhibition
of angiogenesis; and induction of apoptosis. They further exhibit
growth factor-like, mitogenic, and steroidogenic activities [33–35]. In
addition to MMPs, TIMPs can inhibit ADAMs and ADAMTSs, which
contain thrombospondin (TS)-like domains. In particular TIMP-3 is
a major global regulator of MP activity (see [3] and references
therein). More recently, other MMP inhibitors have been
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inducing cysteine-rich protein with Kazal motifs, RECK; tissue-
factor-pathway-inhibitor 2; and procollagen C-terminal proteinase
enhancer. However, the hypothetic mechanisms of action of the
latter inhibitors are still unknown [2].
4. Overall structure of MMP catalytic domains
MMPs have been object of a number of structural studies for the
last 15 years [25,36]. To date, X-ray or NMR structures comprising at
least the catalytic domains, isolated or in complexes with inhibitors,
are available for MMP-1-to-MMP-3, MMP-7-to-MMP-14, MMP-16,
and MMP-20 (see Table 2). The catalytic domain structures are very
similar, in the shape of a sphere with a diameter of ∼40 Å (Fig. 1A). A
shallow active-site cleft lies on the front surface, which entails that
substrates bind in an approximately extended conformation according
to the standard orientation of MPs used here. This orientation entails
that a substrate binds horizontally from left (N-terminal non-primed
side) to right (C-terminal primed side) of the catalytic metal ion
[37,38]. The cleft bifurcates themolecule asymmetrically into an upper
N-terminal (NTS, 127 residues on average; see Table 1) and a lower C-
terminal sub-domain (CTS; 37 amino acids on average). No disulﬁde
bonds are present in any structure and, as foreseeable in a proteinwith
preceding and downstream domains, both termini are surface located,
at the lower left of the molecule (Fig. 1A, B).Fig. 1.MMP catalytic domain structure. (A) Stereographic Richardson-plot of the catalytic dom
The repetitive secondary structure elements (orange arrows for β-strands, βI–βV; cyan ribbo
ions in red) are depicted. The side chains of the zinc-binding histidines, the general base
interactions (grey dots) within the CTS are shown as stick models with yellow carbons an
inhibitor structures (see [40]), is further shown as a stick model with grey carbons. Addition
speciﬁcity loop in red; S1′-wall-forming segment in blue; S-loop in purple; and bulge-edge seg
Close-up view of (A) depicting the side chains engaged in zinc binding and those shaping the
4 and SETOR [89].Depending on the construct employed, the N-terminal α-amino
group of the mature enzymes is either salt-bridged to Asp232
(numbering and description hereafter correspond to MMP-8 unless
otherwise stated; see Protein Data Bank (PDB) entry 1jan; [39]), the
ﬁrst of two conserved vicinal aspartate residues at the beginning of α-
helix αC, the “C-terminal helix” (construct Phe79–Gly242 in the case
of MMP-8; see Fig. 1A) or free and undeﬁned by electron density (e.g.,
until Pro86 in MMP-8 construct Met80–Gly242; [40]). In the ﬁrst case,
which represents the physiologically relevant form, the stabilization
provided by the salt-bridge renders a “superactive” form, with
fourfold-higher activity than the shorter construct in the case of
MMP-8 [39]. In several MMP structures, this salt-bridge is not formed,
thus giving rise to disparate locations of their N-termini (see Fig. 3A in
[25]). In any case, the polypeptide chain subsequently creeps upwards
along the molecular surface to enter the NTS and a ﬁve-stranded
twisted β-sheet that parallels and delimits the active-site cleft on its
top. All strands except the fourth one are parallel and run left to right
(βI–βV; connectivity −1x,+2x,+2,−1; see Fig. 1A, B). The sheet
accumulates a clockwise twist of ∼70° from back to front between βII
and βIV, but is only slightly arched. Two helices (αA, the “backing
helix”, and αB, the “active-site helix”; Fig. 1A, B) nestle into the
concave side of the sheet. They make contact at Ala116 from αA and
Ala196 from αB and their axes lie in the same plane, rotated ∼35°
away. The residues at the interface between the sheet and the helices
are mainly hydrophobic and give rise to an extended centralain of humanMMP-8 (Phe79–Gly242) shown in standard orientation (PDB 1jan; [39]).
ns forα-helices,αA-αC) and the four cations (two zinc ions inmagenta and two calcium
/acid glutamate, the Met-turn methionine, and residues engaged in key electrostatic
d labeled. A substrate of sequence Pro-Leu-Gly-Leu-Ala, modeled based on published
al relevant chain segments are shown in distinct colors and labeled (Met-turn in green;
ment inmagenta). (B) Topology scheme ofMMP-8 in the same orientation as in (A). (C)
speciﬁcity pocket, which are labeled. The ﬁgurewas prepared with programs CARRARA-
Fig. 2. Catalytic mechanism of MMPs. Scheme for the cleavage mechanism proposed for MMPs, with the catalytic zinc ion as a sphere and hydrogen bonds as dashed lines. The three
histidine ligands are represented by sticks. One conceivable alternative is that the second proton is transferred directly from the gem-diolate to the leaving amine in II. and not via the
general base/acid glutamate. This proton transfer could hypothetically occur before or after scissile-bond cleavage.
23C. Tallant et al. / Biochimica et Biophysica Acta 1803 (2010) 20–28hydrophobic core. On the convex side of the sheet, three elements
protrude from the molecular surface: the loop connecting strands βII
and βIII (LβIIβIII), LβIIIβIV, and LβIVβV. These elements are
characteristic for MMPs and distinguish them from other metzincins
[3,4,6]. LβIIβIII and LβIVβV are at the top left and LβIIIβIV at the top
right of the molecule. LβIVβV participates in an octahedral calcium-
binding site made up by threemain-chain carbonyl oxygen atoms, two
solvent molecules, and a carboxylate oxygen from an aspartate
residue, Asp173. LβIIIβIV, called the “S-loop” (see Fig. 1A; [25]),
spans 16 residues andmeanders around two further ion-binding sites:
First, a structural zinc ion is tetrahedrally co-ordinated by three
histidines and, monodentately, by an aspartate (His147, His162,
His175, and Asp149). This cation is indispensable, as a double mutant
disabling metal co-ordination was shown to be inactive. The second
half of the S-loop is engaged in a second octahedral calcium-binding
site (Fig. 1A). Three main-chain carbonyl oxygens and the side chains
of Asp154, Asp177, and Glu180 contribute to the ligand sphere in a
monodentate manner. All residues participating in the three ion-
binding sites are conserved among structurally characterized MMPs
(see Fig. 2 in [25]). In some structures, a third, trigonal-bipyramidal
calcium site is found trapped by LβIαA and LβVαB under participation
of two main-chain carbonyl oxygens and the carboxylate groups of
two acidic groups [25]. After the S-loop, the chain enters the
lowermost, antiparallel strand of the β-sheet, βIV, which delimits
the active-site cleft (see below). After the last strand, βV, the chain
enters a large loop, LβVαB, which is highly variable among MMPs and
contributes to substrate speciﬁcity (see below). This loop leads to the
active-site helix, αB, which comprises the ﬁrst half of an extended
zinc-binding consensus sequence, HEXXHXXGXXH (amino acid one-
letter code; X stands for any residue). The helix includes two histidine
ligands of the catalytic zinc ion, separated by a single helical turn,
which allows a concerted approach to themetal, and the general base/
acid glutamate required for catalysis (see Section 6.). The motif is
conserved not only amongMMPs but also across metzincins [3,4]. The
NTS ends afterαB at the glycine of the consensus sequence and enters
the CTS. This residue allows for a sharp turn in the trajectory of the
polypeptide to reach the third histidine of the motif (in some
metzincins it is replaced by an aspartate; [3]), which is also a zinc-
binding ligand. The values of the main-chain angles of the glycine
(Φ=108°;Ψ=10° in MMP-8) indicate that this residue is required at
this position, as any other amino acid would be in a high-energy
conformation. After the third zinc ligand, a short, structurally
conserved loop adopts the shape of a wide, right-handed spiral. Itfeatures a conserved residue within MMPs, serine or threonine in all
structures analyzed (Ser208 in MMP-8), which is engaged in a strong
electrostatic interactionwith the residue that anchors the N-terminus,
Asp232 (Fig. 1A). After this loop, the chain leads to a tight 1,4-turn of
type I, termed the “Met-turn” due to the invariable residue found at
the third turn position (Met215; see Fig. 1A–C and Section 5.). This
turn is stabilized by a double main-chain interaction with Asp233 of
αC (Fig. 1A). Between the Met-turn and the last helix αC, all MMPs
have a “speciﬁcity loop”, which is important for substrate speciﬁcity
(see Section 5.). This segment runs along the molecular surface from
left to right, before it penetrates themolecular moiety and turns to the
left on the back surface to join αC.
In this conserved scaffold, some MMPs show speciﬁc structural
elements. For example, one insertion, found only in MT-MMPs within
LβIIβIII, termed “MT-loop”, could have an exosite function during pro-
MMP-2 activation. Moreover, in MMP-2 and MMP-9 three ﬁbronectin
type-II repeats are found within LβVαB. They are important for
substrate interaction [25].
5. Active-site cleft and zinc-binding site
The active-site top is delimited by strand βIV and the last part of
the preceding LβIIIβIV, the S-loop. The former outlines the upper-rim
or northern-wall of the active-site crevice and binds a substrate
mainly on its non-primed side through antiparallel β-ribbon like
interactions (see Section 6. and Fig. 2). The latter element was termed
“bulge-edge segment” by K. Maskos and W. Bode [41] and is of great
importance for substrate and inhibitor binding. The cleft bottom is
closed on its primed side by the speciﬁcity loop, which is responsible
for a hydrophobic S1′-substrate binding site or speciﬁcity pocket (see
Section 7.). It displays the largest variations of all the MMPs, which
accounts for the variety in depth and nature of the pocket. The
speciﬁcity loop also contributes to substrate binding through its initial
segment, Pro217-Asn-Tyr219 in MMP-8, termed the “S1′-wall-forming
segment” [41]. The catalytic zinc ion lies at the bottom of the cleft
center (Fig. 1A,C). It is co-ordinated by the Nɛ2 atoms of the three
consensus histidines (His197, His201, and His207) and a catalytic
solvent molecule (substituted by other ligands in the enzyme/
inhibitor complexes) in an approximately tetrahedral manner, with
binding distances of ∼2.1 Å. Below the zinc site, the Met-turn features
an element conserved (even for the conformation of the methionine
side chain) in position and orientation across all metzincins studied
despite disparate upstream and downstream chain traces [3,4]. The
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although the methionine–sulfur is too far away from the metal (6.3 Å
in MMP-8), and its two lone electron pairs do not point towards the
metal. The reason for the strict conservation of the Met-turn is not
clear. Some mutation studies suggested a role in folding and stability
of metzincins but others did not [42–45].
6. Mechanism of peptide-bond cleavage
Based mainly on studies on the distantly related MPs, thermolysin
and carboxypeptidase A, as well as on a number of MMP complexes, aFig. 3. Zymogenic structure of MMPs. (A) Stereographic Richardson-plot of pro-MMP-2 (PDB 1
pro-domain is shown in white and the catalytic moiety in yellow. The magenta arrow points t
disulﬁde-bond (orange sticks), not present in other pro-MMPs (see Fig. 2 in [25]). (B) Close-up
Lys99-Asp106 (stick model with light-grey carbon atoms) and residues of the protease moie
glutamate replaced with glutamine. (C) Superimposition of the structures of pro-MMP-1 (PDB
[58]; pink/magenta;without theﬁbronectin-relateddomains), pro-MMP-3 (PDB1slm, [60]; cya
reﬂect undeﬁned regions. Structure superposition was computed with program RAPIDO [90] asingle-step catalytic mechanism of action was suggested for MMPs
[4,40,46–53]. This mechanism comprises the nucleophilic attack of a
catalytic solvent molecule, polarized by the general base/acid
glutamate and the catalytic zinc ion, on the scissile peptide bond at
close-to-neutral pH values. For this to happen, a substrate must be
bound and form a Michaelis complex (Fig. 2, step I). Binding occurs in
an extended conformation through the S1′-wall-forming segment and
the bulge-edge segment on the primed side and through upper-rim
strand βIV on the non-primed side of the active-site cleft. The scissile
carbonyl group co-ordinates the catalytic zinc ion, which further
ligands the three protein histidines of the zinc-binding consensuseak) without the ﬁbronectin-related domains approximately in standard orientation. The
o the beginning of the mature protease domain (Tyr110). This zymogen displays a unique
view of (A) showing electrostatic interactions (grey dots) between pro-domain segment
ty (sticks with yellow carbon atoms). The structure reported has the general base/acid
1su3, [61]; pro-domain in violet and protease domain in purple), pro-MMP-2 (PDB 1eak,
n/blue), andpro-MMP-9 (PDB1l6j, [62]; yellow/orange). Discontinuities in the chain trace
nd ﬁgures were prepared with programs SETOR and TURBO-FRODO [91].
Fig. 4. Inhibitor complexes of MMP catalytic domains. Close-up view similar to Fig. 1C of MMP catalytic domains in complexes with small-molecule inhibitors. (A) Complex of MMP-8
with BB-1909 (N3-[3S-hydroxy-4-{N-hydroxyamino}-2R-isobutylsuccinyl]amino-1-azacyclotridecan-2-one). This compound displays IC50 values of 20 nM against MMP-8; 30 nM
against MMP-1; 20 nM against MMP-2; 500 nM against MMP-3, and 200 nM against MMP-7 (PDB 1 kbc;[92]). (B) Detail of the complex of MMP-13 with n,n′-bis(4-ﬂuoro-3-
methylbenzyl)pyrimidine-4,6-dicarboxamide, which evinces an IC50-value of 8 nM against MMP-13 and no detectable afﬁnity at 100 μM for MMP-1, -2, -3, -7, -8, -9, -10, -12 -14 and -
16. (PDB 1xud; [74]). (C) Same region of MMP-8 as (A) with 5-carbamoylmethyl-4-oxo-3,4,5,6,7,8-hexahydro-benzo[4,5]thieno[2,3-d]pyrimidine-2-carboxylic acid (3-oxo-3,4-
dihydro-2H-benzo[1,4]oxacin-6-yl-methyl)amide. This compound presents an IC50-value of 7.4 nM against MMP-8,b25 nM against MMP-13, and N2500 nM against MMP-1, -2, -3, -7,
-9, -12, and -14 (PDB 1dng; [75]). The left panel shows the structure after a horizontal 90°-rotation. The ﬁgure was prepared with program SETOR.
25C. Tallant et al. / Biochimica et Biophysica Acta 1803 (2010) 20–28sequence and a solvent molecule in a pentameric fashion. In some
MMP structures, two additional, somewhat labile solvent molecules
were found bound to the zinc [51]. The pentameric zinc ligand sphere
is retained throughout the reaction, although the ion may undergo
local charge transitions during the process [53]. The solvent is further
bound to the glutamate of the zinc-binding consensus sequence,
which acts ﬁrst as a general base and then as an acid during catalysis.
This arrangement entails the solvent becoming extremely polarized
between the glutamate base and the zinc Lewis acid [50]. In addition,
the zinc further exerts Lewis acid activity on the scissile carbonyl
oxygen, thus enhancing the electrophilicity of the carbon [54]. The
scissile nitrogen hydrogen bonds to a main-chain carbonyl of the
upper-rim strand and the hydrophobic P1′-chain is accommodated in
the cognate speciﬁcity pocket. The glutamate base abstracts a proton
from the water (Fig. 2, step I), thus giving rise to a hydroxide that
attacks the scissile carbonyl carbon following a tetrahedral mechan-
ism [55]. This leads the planar carbonyl group to become a negatively-
charged tetrahedral reaction intermediate centered on an sp3-
hybridized gem-diolate group (Fig. 2, step II). The latter interacts in
a bidentate manner with the zinc ion, with one of its hydroxyls
occupying the position of the catalytic solvent in the substrate-
depleted enzyme. The glutamate subsequently acts as a general acid
catalyst, delivering the proton captured from the solvent to the
scissile-bond nitrogen, which becomes a secondary ammonium [56].
The remaining gem-diolate proton is transferred to the secondary
ammonium directly or via the glutamate (Fig. 2, step III) [57]. This
second proton-shufﬂing event results in the reaction intermediate
collapsing to two products containing new carboxylate and α-
ammonium groups, respectively. The two cleavage products remain
initially bound to the enzyme in the form of a double-product complex
[51]. Biophysical studies on a functionally-related MP, ADAM-17,
revealed that product release is actually the rate-limiting step of the
reaction [53]. The newly formed C-terminus interacts with thecatalytic zinc, possibly in a monodentate manner, and the new N-
terminus hydrogen bonds to the glutamate. Subsequently, an incom-
ing solvent molecule binds the zinc ion and separates the new C-
terminus from the general base/acid glutamate carboxylate group.
This facilitates release of the non-primed-side product half, while the
primed-side half remains still bound to the enzyme. Repulsion
between the zinc ion and the new N-terminus leads to a subtle
rearrangement of the bound product half and to reaccommodation of
the P1′ side chain within the speciﬁcity pocket. This entails that the
main-chain interactions of the product with the enzyme are
weakened, eventually leading to product release.
7. Zymogen structure and activation
Except for MMP-23, MMPs are kept under control through pro-
domains and, to date, structures of pro-MMP-1, -2, -3, and -9 have
been reported [58–62] (Fig. 3A–C). They show that the catalytic
domains are already preformed in the zymogen and that pro-domains,
which span between 66 and 91 residues among structurally
characterized MMPs (see Table 1), shield the active-site clefts, thus
preventing substrate access. Such shielding of an already functional
protease moiety also occurs in metallocarboxypeptidases like funne-
lins [47]. In contrast to the latter, however, theMMP pro-domain is not
required for (re)folding of the catalytic moiety [63]. In pro-MMP-2
(PDB 1EAK; [58]), taken hereafter as an example, the 80-residue
domain is globular, with an ellipsoidal shape (Fig. 3A, B). The N-
terminus resides on top of the third ﬁbronectin type-II attachment of
the MMP-2 moiety (see Section 4.). It runs in two segments of
extended conformation preceding the globular part. A similar
arrangement of the N-terminal segment is observed for pro-MMP-9
but not pro-MMP-1 or pro-MMP-3, which lack the ﬁbronectin type-II
domains found in gelatinases (see Section 4. and Fig. 3C). The globular
part is maintained by an extensive hydrophobic core including side
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peptide in extended conformation to block the active-site cleft. This
peptide starts in the outermost right edge of the cleft with Pro100 and
it encompasses a conserved “cysteine-switch” or “velcro” motif
[30,31,64], PRCGXPD (Pro100-Arg-Cys-Gly-Asn-Pro-Asp106 in pro-
MMP-2), which runs parallel to the upper cleft rim, i.e., in the opposite
direction to a bound substrate (Fig. 3B). This segment interacts with
the bulge-edge, the upper-rim, and the S1′-wall-forming segments
through inter-main chain and side-chain/main-chain interactions.
The central cysteine, Cys102, binds the catalytic zinc ion via its Sγ
atom, which replaces the catalytic solvent molecule (see Section 6.).
Together with the three histidine (His403, His407, and His413) Nɛ2
atoms, it gives rise to a tetrahedral metal co-ordination. In addition,
Cys102 Sγ hydrogen binds the general acid/base glutamate and the
pro-domain main-chain at Asn104 N (Fig. 3B). Two residues down-
stream, the latter asparagine (other pro-MMPs display a valine at this
position) partially occupies the S1 pocket and links both main-chain
atoms of upper-rim Ala194 via its side chain. A subsequent proline
residue leads to an invariant aspartate (Asp106), whose double salt-
bridge with Arg101 maintains the required conformation of this
inhibitory sequence (Fig. 3B). At this point, the chain turns back and
approaches the molecular surface of the enzyme. Disparate chain
traces within the distinct pro-MMP structures lead to the beginning of
the mature enzyme moiety (Fig. 3A, C) [58,60–62,65].
Activation of pro-MMPs occurs through removal of the zymogenic
domain by mercurial compounds, chaotropic agents, oxidants,
disulﬁde compounds, alkylating agents, and several proteinases such
as trypsin, plasmin, and other MMPs [66]. All these reagents cause a
conformational change in the molecule that pulls out the cysteine
residue and enables a solvent molecule to enter the zinc co-ordination
sphere and, thus, to generate a functional active site. This, in turn,
enables the enzymes to undergo autoproteolysis to completely
remove the pro-domain. This mechanism may be shared with other
metzincin families, in which conserved cysteine-switch motifs have
been found, such as the ADAMs/adamalysin (conserved motif
PKMCGV, [67,68]; although this is controversial [69]), leishmanolysin
(motif HRCIHD) and pappalysin families (motif CG; [70]).
The resulting mature catalytic domains have different N-termini
depending on the means of activation and they display differences in
activity [39,66]. The physiologically most relevant variant is achieved
through proteolytic processing of the Asn109–Tyr110 peptide bond
in pro-MMP-2 (His99–Phe100 in pro-MMP-3, Gln99–Phe100 in pro-
MMP-1, Gly98–Phe99 in pro-MMP-8, and Arg106–Phe107 in pro-
MMP-9) to render forms that can establish the salt-bridge between
the mature N-terminus and an aspartate of helix αC (Asp436 in
MMP-2; see also Section 4.). In the case of pro-MMP-2, the position
of the new N-terminus entails a ∼20 Å-displacement downwards
with respect to the zymogen. A special case is provided by some
MMPs such as MT-MMPs, in which a speciﬁc recognition sequence
(RX{K/R}R) is inserted before the start of the catalytic domain. This
facilitates intracellular activation by Golgi-associated Kex-2/furin-
like convertases of the subtilisin serine proteinase family prior to
secretion [71].
8. Speciﬁcity pocket and inhibitor design
In MMPs, the main subsites for substrate recognition are the
speciﬁcity pocket, S1′, and, to a lesser extent, S2 [72]. The former is
shaped by elements from helix αB (Leu193, Val194, and His197 in
MMP-8), the Met-turn (Leu214 in MMP-8), and the speciﬁcity loop
(Tyr219, Ala220, Arg222, Tyr227, Leu229, and Pro230 in MMP-8) (Fig.
1C). The speciﬁcity loop greatly diverges in length among MMPs and
encompasses from nine (in MMP-1, -9, -11, and -23) to 13 residues (in
MMP-17 and -25) (see Fig. 1 in [72]). The S1′-pocket has been
considered for the design of small-molecule drugs. Most ﬁrst and
second generation inhibitors were peptide-derived and bound MMPson their primed side (see Section 9.). They contained hydroxamic acid
to ﬁrmly co-ordinate the catalytic zinc and were broad-spectrum
inhibitors of MMPs and other MPs. Examples included batimastat,
marimastat, prinomastat, ilomostat, Ro32-3555, etc. [36,72] (see Fig.
4A). More recently, new strategies have been developed to increase
selectivity among MMPs including alternative, less potent zinc-
binding groups such as phosphinic compounds [73]. They take
advantage of differences in the speciﬁty loop and, thus, the S1′-pocket
[72,74–76]. In some cases, compounds merely targeting the speciﬁcity
pocket rather than the zinc ion were successful (Fig. 4B, C).
Cumulatively, these strategies have given rise to both potent and
speciﬁc inhibitors of MMP-2/9, -12, -8/13, and -13 ([74–79]; see
Fig. 4).
An alternative but still incipient strategy consists of targeting the
general base/acid through covalent modiﬁcation. The proof of concept
was provided in 1992 by the elucidation of the crystal structure of a
funnelin [47], bovine carboxypeptidase A, in complex with 2-benzyl-
3,4-epoxybutanoic acid. Its oxirane group acted as a suicide inhibitor
and covalently modiﬁed one of the two glutamate carboxylate
oxygens [80,81]. More recently, this strategy has led to a new
generation of “mechanism-based inhibitors”, which contain a thiirane
group to target the glutamate. They were shown to display signiﬁcant
selectivity for MMP-2 over other MMPs [82,83].
9. Prospects
Since the ﬁnding more than 30 years ago that MMPs were capable
of degrading essentially all structural components of the ECM and that
they were massively up-regulated in a wide spectrum of pathologies,
they were heralded as promising targets for the design of new drugs.
Initial steps in search for an orally bioavailable small-molecule MMP
inhibitor were undertaken in the late 1970s for the treatment of
arthritis [84]. Later, the results of preclinical studies of MMP inhibitors
were so successful that their design was rapidly optimized and they
soon entered human clinical trials. Particularly promising scenarios
were cancer and metastasis, arthritis, and atherosclerosis [76,85].
However, these trials failed to reach their end points as severe side
effects were observed. The main reasons adduced were that while
some MMPs promote pathology, others have a protective effect
[86,87]. In addition, most of the inhibitors assayed were not selective,
and they inhibited several MMPs simultaneously with similar afﬁnity,
even other MPs such as ADAMs/adamalysins [76]. As a result, only
periostat (doxycycline hyclate) received FDA approval in 2001, and
then only for the treatment of periodontitis [36]. Therefore, efforts
have since been redirected a more detailed examination of the
temporary and spatial roles of each MMP in the distinct pathologies
[15,72]. Another approach contemplated the development of extre-
mely selective inhibitors to reliably distinguish between MMPs, and
included the consideration of exosites [25,88]. However, despite
considerable chemical efforts in recent years, only a few highly
selective synthetic inhibitors have been identiﬁed so far [76]. That is
why detailed knowledge of the atomic structure of the particular
MMPs to be targeted—ten MMPs still await structural characterization
of their catalytic domains—and of their complexes with inhibitors is
an urgent requirement.
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